BKM120 as Second-line Therapy for Advanced Endometrial Cancer

Exclusion Criteria

• •previous treatment with PI3K and/or mTOR inhibitors
• •symptomatic CNS metastases
• •concurrent malignancy or malignancy within 3 years of study enrollment
• •Active mood disorder as judged by investigator or medically documented history of mood disorder (e.g. major depressive episode, bipolar disorder, obsessive-compulsive disorder, schizophrenia, etc.), ≥ CTCAE grade 3 anxiety
• •pelvic and/or para-aortic radiotherapy ≤ 28 days prior to enrollment in the study
• •poorly controlled diabetes mellitus (HbA1c \> 8 %)
• •history of cardiac dysfunction or active cardiac disease as specified in the protocol
• •impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of BKM120